DURECT Corporation

Equities

DRRX

US2666055007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-20 EDT			5-day change	1st Jan Change
1.04 ^USD	+11.83%		-2.80%	+76.27%

05-14	Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	MT
05-13	Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024

Jay Shepard to Resign from the Board and Nominating and Corporate Governance Committee of DURECT Corporation, Effective August 16, 2016

August 09, 2016 at 04:06 pm

On August 4, 2016, Jay Shepard provided notice to the board of directors of DURECT Corporation of his decision to resign from the Board and its Nominating and Corporate Governance Committee effective August 16, 2016.

Latest news about DURECT Corporation

Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	05-14	MT
Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024	05-13
Earnings Flash (DRRX) DURECT CORPORATION Reports Q1 Revenue $1.8M, vs. Street Est of $2.7M	05-13	MT
Transcript : DURECT Corporation, Q4 2023 Earnings Call, Mar 27, 2024	03-27
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M	03-27	MT
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
North American Morning Briefing : Stocks Edge -2-	03-27	DJ
North American Morning Briefing : Stock Futures -2-	03-19	DJ
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada	03-04	CI
DURECT Corporation(NasdaqCM:DRRX) dropped from S&P Global BMI Index	12-18	CI
Transcript : DURECT Corporation, Q3 2023 Earnings Call, Nov 13, 2023	11-13
Earnings Flash (DRRX) DURECT CORPORATION Reports Q3 Revenue $1.7M, vs. Street Est of $2.5M	11-13	MT
DURECT Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
North American Morning Briefing : Investors Weigh -2-	11-10	DJ
JonesTrading Downgrades Durect to Hold From Buy	11-09	MT
North American Morning Briefing : Traders Await -2-	11-09	DJ
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	11-08	MT
Sector Update: Health Care	11-08	MT
Top Midday Decliners	11-08	MT
HC Wainwright Downgrades Durect to Neutral From Buy	11-08	MT
Top Premarket Decliners	11-08	MT
Transcript : DURECT Corporation - Special Call	11-07
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality	11-07	CI
Durect Corporation Announces Last Patient Last Visit in Phase 2B Ahfirm Trial of Larsucosterol in Alcohol-Associated Hepatitis	23-09-07	CI

Chart DURECT Corporation

Duration

Period

More charts

Company Profile

DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Sector

Biotechnology & Medical Research

Calendar

2024-06-08 - European Association for the Study of the Liver Congress - Abstract No. LB73

More about the company

Income Statement Evolution

More financial data

Ratings for DURECT Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.93 USD

Average target price

8.5 USD

Spread / Average Target

+813.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DURECT CORPORATION	+76.27%	28.86M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs